entertainment -WSS

entertainment

author：comprehensive 2025-08-23 05:00:46 - browse：581

Three boxes of Breyanzi on a dark blue background — biotech coverage from STAT — The FDA is looking into adverse events involving a number of CAR-T therapies, including Breyanzi. Illustration: STAT; Source: Business Wire

The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which uses genetically modified white blood cells to attack tumors, can in rare cases cause lymphoma, a blood cancer.

“Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action,” the agency said in a statement.

The agency noted that it is investigating reports of T cell lymphoma, including cancer cells carrying the engineered T cells, in patients who received CAR-T therapy. Experts in the field, which has produced multiple approved products to treat blood cancer, expressed surprise and puzzlement at the announcement, saying that they had not previously seen data about the risk.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Wildfire pollution widens asthma inequities on Long Island

entertainment

focus

WSS

Medicare Advantage overpayments discussion gets experts fired up

Medicare Advantage overpayments discussion gets experts fired up

A preacher's new calling: Diversifying neuroscience research

NIH launches clinical trials and new research office for long Covid

Gene therapy denied for Afghan refugee whose father aided U.S.

The high personal cost of affirmative action for Black doctors

entertainment

entertainment

focus

Life science postdocs should get big pay hike, NIH panel says

Affirmative action in medical school literally saved lives

No plane should take off without an EpiPen onboard

ChatGPT in medicine: STAT answers readers' burning questions

Medicare Advantage overpayments discussion gets experts fired up

DIEP, the 'gold standard' of breast reconstruction, is under threat

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Duchenne breakthrough therapy leaves behind pioneering families

Boston Scientific acquires urology company Axonics for $3.7 billion

knowledge

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Nonprofit, backed by Microsoft, to certify AI tools in health care

Medicare Advantage coverage denials need scrutiny, senators say

Merck to acquire Harpoon Therapeutics for $680 million

Vertex non

The high personal cost of affirmative action for Black doctors

entertainment

focus

focus

focus